Cisplatin cancer

Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland RC, Koi N, Fishel R, Howell SB (1996) Loss of DNA mismatch repair. in acquired resistance to cisplatin. Cancer Res 56 3087-3090... [Pg.60]

Andrews PA. Mechanisms of acquired resistance to cisplatin. Cancer Treat Res 1994 73 217-248. [Pg.58]

Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993 53 4633-4636. [Pg.174]

R. Schierl, B. Rohrew, J. Hohnloser, Long-term platinum excretion in patients treated with cisplatin, Cancer Chemother. Pharmac., 36 (1995), 75 D78. [Pg.374]

Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, Schellens JM. Phase I and pharmacokinetic study of SPI-77, a hposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 2002 49(3) 201-10. [Pg.2866]

Sweeney JD, Ziegler P, Pruet C, Spaulding MB. Hyperzincuria and hypozincemia in patients treated with cisplatin. Cancer 1989 63(ll) 2093-5. [Pg.2869]

Safirstein RL, Daye M, Guttenplan JB. Mutagenic activity and identification of excreted platinum in human and rat urine and rat plasma after administration of cisplatin. Cancer Letters 1983 18 329-38. [Pg.527]

Cisplatin Cancer Nephrotoxicity, peripheral neurotoxicity, and hearing loss TPMT GST COMT [99, 101]... [Pg.676]

Farrell, N. Non classical platinum antitumor agents perspectives for design and development of new drugs complementary to cisplatin. Cancer Invest. 1993, 77, 578-589. [Pg.59]

Ceul M, van Waardenburg RC, Beijnen JH and ScHELLENS JHM (2002) DNA-based drug interactions of cisplatin. Cancer Treat Rev 28(6) 291-303. [Pg.1077]

LeBlanc, G.A., P.W. Kantoff, S.F. Ng, E. Frei 3rd, and D.J. Waxman (1992). Hormonal perturbations in patients with testicular cancer treated with cisplatin. Cancer 69, 2306-2310. [Pg.376]

Cavaletti G, Bogliun G, I rzorati L, Zincone A, Marzola M, Colombo N, Tredici G, Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer (1995) 75, 1141-50,... [Pg.661]

Chemonics International Inc (2001) Biodiversity assessment for Uzbekistan, task order under the biodiversity sustainable forestry. KJC (BIOFOR) USAID contract number LAG-I-00-99-00014-00, submitted to USAID Central Asian Republics Mission, Almaty. http //pdf.usaid.gov/pdf docs/PNACN475.pdf. Accessed 22 Feb 2007 Chen G, Todorov DK, ZeUer WJ (1992) Antitumor activity of thaliblas-tine (NSC-68075) in experimental ovarian tumor cell tines sensitive and resistant to cisplatin. Cancer Lett 62(2) 173—177 Chen B, Teranishi R, Kawazoe K, Takaishi Y, Honda G, Itoh M, Takeda Y, Kodzhimatov OK (2000) Sesquiterpenoids from Ferula kuMs-tanica. Phytochemistry 54(7) 717-722 Chen J, Shi Y, Liu J (2003) Determination of noradrenaline and dopamine in Chinese herbal extracts fiom Portulaca oleracea L. by high-performance liquid chromatography. J Chromatogr A 1003(1-2) 127-132... [Pg.303]

Okuyama T, Maehara Y, Endo K, Baba H, Adachi Y, Kuwano M, Sugimachi K (1994) Expression of glutathiraie S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer 74(4) 1230-1236... [Pg.337]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...